Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anura Abeyratne"'
Autor:
Bruce E. McNutt, Sanjay Kalra, Michael J. Koren, Sally Klasen, Anura Abeyratne, Abdullah Hamad
Publikováno v:
American Journal of Health-System Pharmacy. 68:818-827
Purpose The efficacy and safety of conivaptan administered via 30-minute i.v. infusion to patients with euvolemic or hypervolemic hyponatremia were evaluated. Methods Hospitalized adults with a baseline serum sodium concentration (SSC) of 115–130 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca5ba33accc2d47b3bad0099f72a81b
https://doi.org/10.2146/ajhp100260
https://doi.org/10.2146/ajhp100260
Autor:
Lisa C. Plumb, James Keirns, Dennis Riff, Keith A. Erdman, Anura Abeyratne, Michael Roy, Kenneth C. Lasseter
Publikováno v:
Clinical pharmacokinetics. 52(5)
Conivaptan is a non-peptide dual antagonist of vasopressin V1A and V2 receptors that is approved in the United States as an intravenous formulation for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. The pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bcf9f6b75a78a8fd87c80f1aa410985
https://pubmed.ncbi.nlm.nih.gov/23456393
https://pubmed.ncbi.nlm.nih.gov/23456393
Autor:
James Keirns, Albert Dietz, Ronald A. Smulders, Takeshi Kadokura, Wenhui Zhang, Walter Krauwinkel, Anura Abeyratne
Publikováno v:
Clinical therapeutics. 35(8)
Ipragliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, is in development for the treatment of type 2 diabetes mellitus. The International Conference on Harmonisation recommends that the safety investigation of new drugs include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebde9efb29b70a8a67e924755b9751d1
https://pubmed.ncbi.nlm.nih.gov/23910665
https://pubmed.ncbi.nlm.nih.gov/23910665
Autor:
Juan Carlos Q. Velez, Bruce E. McNutt, Shai Efrati, Anura Abeyratne, Arie Oliven, Sally Klasen, John M. Arthur, Sanjay Kalra
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 68(7)
Purpose The effect of loading dose and formulation on the safety and efficacy of conivaptan in the treatment of euvolemic and hypervolemic hyponatremia was studied. Methods This parallel-group study randomized 121 hospitalized patients with euvolemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ce5f98cda285861e7156e8fde841855
https://pubmed.ncbi.nlm.nih.gov/21411800
https://pubmed.ncbi.nlm.nih.gov/21411800
Autor:
Yumiko Aoyama, Takahito Nakahara, Ying J. Cao, Toru Kakihara, Joyce Steinberg, Jimmy Wang, Anne Keating, Taiji Sawamoto, Anura Abeyratne, Masataka Katashima, Michael Roy
Publikováno v:
Molecular Cancer Therapeutics. 8:C134-C134
Survivin is a member of IAPs. YM155 is a compound that suppresses survivin, and has been shown to exhibit anti-tumor activity in preclinical and clinical studies. The current analysis is designed to compare the pharmacokinetics (PK) of YM155 between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb29a49e90228db5c39bb04992671495
https://doi.org/10.1158/1535-7163.targ-09-c134
https://doi.org/10.1158/1535-7163.targ-09-c134